

## GENETICS AND GENOMICS DIAGNOSTIC LABORATORY

For local courier service and/or inquiries, please contact 513-636-4474 • Fax: 513-636-4373  $www.cincinnatichildrens.org/diagnosticlabs \bullet Email: LabGeneticCounselors@cchmc.org$ 

Mailing Address:

3333 Burnet Avenue, Room R1042 Cincinnati, OH 45229

## **ONCOLOGY GENETIC TESTING REQUISITION**

## All Information Must Be Completed Before Sample Can Be Processed

## **PATIENT INFORMATION**

Patient Name:			
Last		First	MI
Address:			
Home Phone:		MR#:	
Date of Birth://	/	_ Gender: 🗆 Male 🗆 Female	

## INDICATIONS/DIAGNOSIS/ICD-9 CODE

□ Acute Myelogenous Leukemia	🗖 Glioma	Lymphoproliferative Disorder	🗖 Pancytopenia
□ Acute Promyelocytic Leukemia	🗖 Hodgkin Lymphoma	🗆 Malignant Melanoma	Delycythemia Vera (PV)
□ Adenopathy	□ Langerhans Cell Histiocytosis (LCH)	🗆 Medulloblastoma	🗆 Sarcoma
🗆 Anemia	🗖 Leukemia	□ Monoclonal Gammopathy	□ Thrombocytopenia
Burkitt Lymphoma	□ Leukocytosis	□ Multiple Myeloma	□ Thrombocytosis
Chronic Lymphocytic Leukemia	🗖 Leukopenia	□ Myelodysplastic Syndrome/Disease (MDS)	□ Wilms Tumor
Chronic Myelogenous Leukemia	□ Lung Cancer	□ Myeloproliferative Disease (MPS or MPD)	□ Other
Colorectal Cancer	□ Lymphocytosis	🗆 Neutropenia	
Ewing Sarcoma	🗆 Lymphoma	🗆 Non-Hodgkin Lymphoma (NHL)	

## ETHNIC/RACIAL BACKGROUND (Choose All)

🗆 European American (White)	🗆 African-American (Black)
□ Native American or Alaskan	Asian-American
Pacific Islander	🗆 Ashkenazi Jewish ancestry
□ Latinx-Hispanic (specify country/region of origin)	
Other	
(specify country/region of origin)	

## **REFERRING PHYSICIAN**

Physician Name (print):		
Address:		
Phone: ()	Fax: (	)
Email:		
Genetic Counselor/Lab Contact Name:		
Phone: ( )		
Email:		
Referring Physician Signature (REQUIRE		Date:///
Contact Information for Results/Question	ns ( <i>if differe</i> l	nt than ordering provider) :
Name & Title:		
Phone: ()	=ax: ()	

Email: \_

## **BILLING INFORMATION (Choose ONE method of payment):**

Institution:
Address:
City/State/Zip:
Accounts Payable Contact Name:
Phone:
Fax:
Email:

#### □ COMMERCIAL INSURANCE

Insurance can only be billed if requested at the time of service.

Policy Holder Name:	 	
Gender:		
Authorization Number:	 	
Insurance ID Number:	 	
Insurance Name:	 	
Insurance Address:	 	
City/State/Zip:	 	
Insurance Phone Number:	 	

See page 3 for more billing information



#### SAMPLE/SPECIMEN INFORMATION

	DISEASE STATUS:	
Has patient received a bone marrow transplant? 🛛 Yes 🖓 No	$\Box$ New diagnosis $\Box$ Remission $\Box$ Relapse $\Box$ E(COG) study $\Box$ COG patient	
If yes, date of bone marrow transplant	SPECIMEN TYPE — SEE PAGE 3 FOR SPECIMEN REQUIREMENTS	
Percent engraftment	$\Box$ Bone marrow $\Box$ Oncology blood $\Box$ Lymph node	
	$\Box$ Formalin fixed paraffin embedded tissue $\Box$ Touch prep $\Box$ Smear	
	Estimated percent of tumor in sample:	
Specimen Date: Time:		
DRAWN BY:	Estimated percent of tumor in sample:	
*Philopotomist must initial tube of specimen to confirm sample identity	Other: WBC % Blasts	

\*Phlebotomist must initial tube of specimen to confirm sample identity

#### **TEST(S) REQUESTED**

#### **SEE PAGE 3 FOR SPECIMEN AND TEST DETAILS**

#### Cytogenetic Chromosome and Microarray Analysis

- $\Box$  Oncology Chromosome Analysis
- Constitutional (blood) Chromosome Analysis

#### Oncology Microarray

[Additional 3 mL blood or bone marrow (NaHep) if ordered without chromosomes] - % Tumor: \_

#### FISH

#### (Additional FISH probes available. See page 3 for details.)

□ t(9;22) [BCR/ABL1]  $\Box X/Y$  [Opposite sex BMT]

□ 11q23 [KMT2A] 🗖 t(15;17) [PML/RARa]

#### **Hematologic FISH Panels**

□ Other (please call lab) \_\_\_\_

#### (All probes available individually. Please see page 3 for panel descriptions)

□ ALL Hyperdiploid	🗆 Fanconi anemia
□ ALL Risk Stratification	□ Multiple myeloma
B-Cell ALL	□ MDS
□ Ph-like ALL	□ Myeloid Malignancy
□ AML	□ MPD
□ APL	□ SDS
🛛 Burkitt Lymphoma	□ Large cell NHL
	□ Small cell NHL
Double Hit Lymphoma	□ Combined NHL
🗖 Eosinophilia	T-Cell Lymphoma/Leukemia

#### **Non-Hematologic FISH**

Fresh tumor or FFPE slides (include 1 marked H&E slide with FFPE) See page 3 for specimen requirements BRAF (7q34) FISH

- Ependymoma FISH Panel
- □ High-Grade Glioma FISH Panel
- Low-Grade Glioma FISH Panel
- Lung Cancer FISH Panel
- □ Medulloblastoma FISH Panel
- □ Melanocytic Tumor FISH Panel
- □ Pilocytic Astrocytoma FISH Panel

#### Molecular Genetic Analysis (RNA assays)

Samples must be received within 24 hours of collection.

- □ BCR/ABL- QUANTITATIVE (p210)
- BCR/ABL- QUANTITATIVE (p190)
- □ BCR/ABL RT-PCR (QUALITATIVE)
- D PML/RARa RT-PCR

#### Molecular Genetic Analysis (DNA assays)

Samples must be received within 48 hours of collection.

□ JAK2 QUANTITATIVE (V617F)

- D PTEN sequencing
- Bone marrow engraftment (BME) by STR (Same sex donor & recipient)
  - Pre-transplant host sample
  - Post transplant sample
  - Donor sample

□ WBC sub-populations engraftment study\*

- □ STR (same sex) [Select cell type(s) and prioritize below]
- □ X/Y FISH (opposite sex) [Select cell type(s) and prioritize below]

□ T cells (CD3+) - Priority: □ 1st □ 2nd □ 3rd □ 4th □ Myeloid cells (CD15+) - Priority: □ 1st □ 2nd □ 3rd □ 4th □ B cells (CD19+) - Priority: □ 1st □ 2nd □ 3rd □ 4th □ NK cells (CD56+) - Priority: □ 1st □ 2nd □ 3rd □ 4th

Cell Separation (for non-engraftment testing)\* [Select cell type(s) and prioritize below]  $\Box$  T cells (CD3+) - Priority:  $\Box$  1st  $\Box$  2nd  $\Box$  3rd  $\Box$  4th  $\Box$  Myeloid cells (CD15+) - *Priority*:  $\Box$  1st  $\Box$  2nd  $\Box$  3rd  $\Box$  4th  $\square$  B cells (CD19+) - Priority:  $\square$  1st  $\square$  2nd  $\square$  3rd  $\square$  4th □ NK cells (CD56+) - Priority: □ 1st □ 2nd □ 3rd □ 4th

#### \* You MUST call the GENETICS LAB at 513-636-4474 to schedule this test prior to sample submission.

#### **Non-Hematologic Genetic Analysis**

□ MAP2K1 full gene sequence analysis (Langerhans cell histocystosis, colon, lung,

melanoma) — % Tumor: \_\_\_

Please see the **Pediatric/Adult Requisition** for

Chromosome Breakage Study for Fanconi Anemia or contact the lab at: www.cincinnatichildrens.org/cytogenetics or 513-636-4474



## **SPECIMEN REQUIREMENTS**

#### Cytogenetic Analysis (Chromosome, FISH, and Microarray analysis):

**3 mL blood or bone marrow (NaHep)** Chromosome analysis Cell culture only FISH probes and FISH panels **3 mL blood or bone marrow (EDTA)** Oncology microarray Fresh Tumor or Lymph Nodes (1cm<sup>3</sup> in sterile saline or sterile transport media) Chromosome analysis Cell culture FISH probes and FISH panels

### Molecular Genetic Analysis (RNA Assays): 5-10 mL blood or 3–5 mL bone marrow (EDTA) — Samples must be received within 24 hours of collection. BCR/ABL — Quantitative (p210), BCR/ABL — Quantitative (p190), BCR/ABL — Qualitative, PML/RARa — Quantitative

Molecular Genetics Analysis (DNA Assays): 3 mL bone marrow or blood (EDTA) — Samples must be received within 48 hours of collection. JAK2 Quantitative (V617F), PTEN Seq, Bone marrow engraftment by STR, WBC sorted sub-populations engraftment study (by STR or FISH)

#### Non-Hematologic Genetic Analysis:

#### MAP2K1 full gene sequencing:

3 mL blood or bone marrow (EDTA), or 1 cm<sup>3</sup> fresh tumor.

#### FISH (Fluorescence In Situ Hybridization)

#### NOTE: All FISH probes are available for individual testing

#### Hematologic FISH Panels — 3 mL blood or bone marrow (NaHep)

- ALL Hyperdiploid: trisomy 4, 10, 17
- ALL Risk Stratification: 4, 10, 17, t(1;19), t(12;21), t(9;22), KMT2A
- B-Cell ALL: *CRLF2*, t(1;19), *ABL2*, 4/10/17, *CSF1R*, *PDGFRB*, *JAK2*, *ABL1*, t(9;22), *KMT2A*, t(12;21), *IGH*, *EPOR*
- Ph-like ALL: CRLF2, ABL2, PDGFRB, CSF1R, JAK2, ABL1, EPOR
- AML: t(6;9), t(8;21), NUP98, KMT2A, inv(16)
- APL: t(15;17), RARa
- Burkitt Lymphoma: t(8;14), MYC
- CLL: 13q14.3, 13q34, 12 centromere, ATM, TP53, t(11;14)
- Double Hit Lymphoma: BCL6, MYC, t(8;14), t(14;18)
- Eosinophilia: 4q12, PDGFRB, FGFR1, CBFB
- · Fanconi Anemia: 1q25, 3q27, mono 7 / del(7q)
- Multiple Myeloma (CD138+): 1p32.3/1q21, t(4;14), t(11;14), monosomy 13/ del 13q, t(14:16), t(14:20), *TP53*
- MDS: mono 5/del 5q, mono 7/del 7q, tri 8, TP53, del (20q)
- Myeloid Malignancy: mono 5/del 5q, t(6;9), mono 7/del 7q, tri 8, t(8;21), NUP98, KMT2A, ETV6, t(15;17), inv(16), TP53, del (20q)

- MPD: 4q12, PDGFRB, FGFR1, BCR/ABL1
- SDS: mono 7/del 7q, tri 8, del (20q)
- Large cell NHL: t(11;14), t(14;18), TP53 , BCL6, ALK
- Small B-cell NHL: t(11;14), t(14;18), 18q21 (MALT1), CLL Panel
- · Combined NHL: (large and small cell NHL panels)
- T-Cell Lymphoma: TRA/TRD, TRB; TRG, BCR/ABL1, KMT2A

# Non-Hematologic FISH Panels — 4-8 FFPE slides cut to 4 micron thickness and 1 marked H & E slide<sup>+\*</sup> — Fresh Tumor (1cm<sup>3</sup>)

- Ependymoma: ABL2, CDKN2A, C11orf95, RELA, YAP1
- High-Grade Glioma: PDGFRA, CDKN2A, NTRK2, MYCN
- Low-Grade Glioma: TP73/ABL2, FGFR1, MYB, BRAF, MYBL1
- Lung Cancer: ALK, ROS1, MET, RET
- Medulloblastoma : MYB, LIS1/RARa, MYC, MYCN
- Melanocytic Tumor: RREB1, MYC, CDKN2A, CCND1
- Pilocytic Astrocytoma: BRAF, CDKN2A\*

<sup>†</sup>For each probe ordered, send 2 unstained slides with one section cut to 4 micron thickness and mounted on a charged slide. Blocks are also accepted for processing. <sup>\*</sup>Pilocytic Astrocytoma FISH Panel only needs 2-4 FFPE slides and 1 marked H&E slide

## **SHIPPING INFORMATION**

#### Local courier is available; please call 513-636-4474 for information.

Shipping for samples that arrive Monday–Saturday:

Cincinnati Children's Genetics and Genomics Diagnostic Laboratory 3333 Burnet Ave. TCHRF 1042 DOCK 5 Cincinnati, OH 45229-3039

## **BILLING INFORMATION**

#### \* PLEASE NOTE:

• We will not bill Medicaid, Medicaid HMO, or Medicare except for the following: CCHMC Patients, CCHMC Providers, or Designated Regional Counties.

• If you have questions, please call 1-866-450-4198 for complete details.

#### □ Patient Signed Completed ABN:

Medical Necessity Regulations: At the government's request, the Molecular Genetics Laboratories would like to remind all physicians that when ordering tests that will be paid under federal health care programs, including Medicare and Medicaid programs, that these programs will pay only for those tests the relevant program deems to be (1) included as covered services, (2) reasonable, (3) medically necessary for the treatment and diagnosis of the patient, and (4) not for screening purposes.